## Richard De Abreu Lourenco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5257314/publications.pdf

Version: 2024-02-01

73 papers 1,066 citations

430442 18 h-index 28 g-index

74 all docs

74 docs citations

74 times ranked 1577 citing authors

#	Article	IF	CITATIONS
1	A prospective randomized multicentre study of the impact of galliumâ€68 prostateâ€specific membrane antigen (PSMA) PET/CT imaging for staging highâ€risk prostate cancer prior to curativeâ€intent surgery or radiotherapy (proPSMA study): clinical trial protocol. BJU International, 2018, 122, 783-793.	1.3	96
2	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. European Urology, 2021, 79, 413-418.	0.9	52
3	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer, 2018, 18, 1030.	1.1	50
4	Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II). JAMA Oncology, 2021, 7, 1476.	3.4	50
5	Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study. Value in Health, 2007, 10, 451-456.	0.1	48
6	Carrots and sticks—the fall and fall of private health insurance in Australia. , 1999, 8, 653-660.		47
7	Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of Clinical Oncology, 2020, 38, 3032-3041.	0.8	37
8	Risk stratification in children with cancer and febrile neutropenia: A national, prospective, multicentre validation of nine clinical decision rules. EClinicalMedicine, 2020, 18, 100220.	3.2	34
9	Bisphosphonate infusions: patient preference, safety and clinic use. Supportive Care in Cancer, 2004, 12, 463-466.	1.0	32
10	Predicting Infectious ComplicatioNs in Children with Cancer: an external validation study. British Journal of Cancer, 2017, 117, 171-178.	2.9	31
11	Re-evaluating and recalibrating predictors of bacterial infection in children with cancer and febrile neutropenia. EClinicalMedicine, 2020, 23, 100394.	3.2	28
12	Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost. Journal of Human Nutrition and Dietetics, 2020, 33, 811-821.	1.3	28
13	Best Evidence to Best Practice: Implementing an Innovative Model of Nutrition Care for Patients with Head and Neck Cancer Improves Outcomes. Nutrients, 2020, 12, 1465.	1.7	23
14	Costâ€effectiveness of term induction of labour using inpatient prostaglandin gel versus outpatient Foley catheter. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2015, 55, 440-445.	0.4	22
15	"The Whole Game is Changing and You've Got Hope― Australian Perspectives on Treatment Decision Making in Spinal Muscular Atrophy. Patient, 2020, 13, 389-400.	1.1	22
16	SCORE: Shared care of Colorectal cancer survivors: protocol for a randomised controlled trial. Trials, 2017, 18, 506.	0.7	21
17	Online, Group-Based Psychological Support for Adolescent and Young Adult Cancer Survivors: Results from the Recapture Life Randomized Trial. Cancers, 2021, 13, 2460.	1.7	21
18	Home-based care of low-risk febrile neutropenia in childrenâ€"an implementation study in a tertiary paediatric hospital. Supportive Care in Cancer, 2021, 29, 1609-1617.	1.0	20

#	Article	IF	Citations
19	Safety and cost analysis of an 18FDG-PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. Oral Oncology, 2015, 51, 529-535.	0.8	19
20	Longâ€term healthâ€related quality of life in young childhood cancer survivors and their parents. Pediatric Blood and Cancer, 2021, 68, e29398.	0.8	19
21	Factors affecting general practitioner charges and Medicare bulkâ€billing: results of a survey of Australians. Medical Journal of Australia, 2015, 202, 87-90.	0.8	18
22	Finding Out What Matters in Decision-Making Related to Genomics and Personalized Medicine in Pediatric Oncology: Developing Attributes to Include in a Discrete Choice Experiment. Patient, 2020, 13, 347-361.	1.1	17
23	Cost-Effectiveness of 12-Month Treatment With Ticagrelor Compared With Clopidogrel in the Management of Acute Coronary Syndromes. Clinical Therapeutics, 2013, 35, 1110-1117.e9.	1.1	16
24	Community preferences in general practice: important factors for choosing a general practitioner. Health Expectations, 2016, 19, 26-38.	1.1	16
25	Reviewing the costâ€effectiveness of longâ€acting reversible contraceptive methods in an Australian context. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2019, 59, 21-35.	0.4	16
26	The Preferred Qualities of Human Immunodeficiency Virus Testing and Self-Testing Among Men Who Have Sex With Men: A Discrete Choice Experiment. Value in Health, 2020, 23, 870-879.	0.1	16
27	External Validation of Six Pediatric Fever and Neutropenia Clinical Decision Rules. Pediatric Infectious Disease Journal, 2018, 37, 329-335.	1.1	15
28	Investigating the relative value of health and social care related quality of life using a discrete choice experiment. Social Science and Medicine, 2019, 233, 28-37.	1.8	15
29	Audit of endometrial biopsy at outpatient hysteroscopy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2008, 48, 202-206.	0.4	13
30	Grandparents of children with cancer: Quality of life, medication and hospitalizations. Pediatric Blood and Cancer, 2017, 64, 163-171.	0.8	13
31	The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial. Trials, 2018, 19, 397.	0.7	13
32	Diagnostic Yield of Initial and Consecutive Blood Cultures in Children With Cancer and Febrile Neutropenia. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 125-130.	0.6	12
33	Costs and consequences of an intervention-based program to reduce hospital-acquired pressure injuries in one health district in Australia. Australian Health Review, 2019, 43, 516-525.	0.5	11
34	Surveillance Improves Outcomes for Carriers of <i>SDHB</i> Pathogenic Variants: A Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1907-e1916.	1.8	11
35	Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leukemia and Lymphoma, 2006, 47, 1069-1081.	0.6	10
36	Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness. Pharmacoeconomics, 2015, 33, 561-569.	1.7	10

#	Article	IF	Citations
37	Examining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents. EClinicalMedicine, 2021, 40, 101095.	3.2	10
38	Patterns and drivers of health care use in long-term childhood cancer survivors: A systematic review. Critical Reviews in Oncology/Hematology, 2017, 120, 60-76.	2.0	9
39	Tell me once, tell me soon: parents' preferences for clinical genetics services for congenital heart disease. Genetics in Medicine, 2018, 20, 1387-1395.	1.1	9
40	Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the ALLG MM6 multicentre, open-label, randomised phase 3 study. Lancet Haematology,the, 2014, 1, e112-e119.	2.2	8
41	Procalcitonin and Interleukin-10 May Assist in Early Prediction of Bacteraemia in Children With Cancer and Febrile Neutropenia. Frontiers in Immunology, 2021, 12, 641879.	2.2	8
42	Costâ€effectiveness of homeâ€based care of febrile neutropenia in children with cancer. Pediatric Blood and Cancer, 2022, 69, e29469.	0.8	8
43	Managing lowâ€risk febrile neutropenia in children in the time of <scp>COVID</scp> â€19: What matters to parents and clinicians. Journal of Paediatrics and Child Health, 2021, 57, 826-834.	0.4	7
44	Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values. Quality of Life Research, 2020, 29, 1483-1494.	1.5	6
45	Giving a Voice to Marginalised Groups for Health Care Decision Making. Patient, 2021, 14, 5-10.	1.1	6
46	A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients. Value in Health, 2022, 25, 47-58.	0.1	6
47	Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. Oncology and Therapy, 2016, 4, 103-116.	1.0	5
48	Valuing families' preferences for drug treatment: a discrete choice experiment. Addiction, 2020, 115, 690-699.	1.7	5
49	Understanding decisions to participate in genomic medicine in children's cancer care: A comparison of what influences parents, health care providers, and the general community. Pediatric Blood and Cancer, 2021, 68, e29101.	0.8	5
50	Thalidomide Consolidation Post Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) Is Cost-Effective With Durable Survival Benefit At 5 Years Post Randomisation: Final Analysis Of The ALLG MM6 Study. Blood, 2013, 122, 537-537.	0.6	5
51	Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: A discrete choice experiment. Developmental Medicine and Child Neurology, 2022, 64, 753-761.	1.1	5
52	Paying for the expanding role of primary care in cancer control. Lancet Oncology, The, 2015, 16, 1228-1229.	5.1	4
53	Is low-priced primary care bad for quality? Evidence from Australian general practice. Applied Economics, 2018, 50, 475-491.	1.2	4
54	Comparing the cost of preparing matched unrelated donor and TCR $\hat{l}_{sup} + \langle sup \rangle \hat{l}_{sup} + \langle sup \rangle \hat{l}_{$	0.5	4

#	Article	IF	CITATIONS
55	Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, S3-S4.	0.4	4
56	Whither private health insurance?. Australian and New Zealand Journal of Public Health, 1997, 21, 119-120.	0.8	3
57	Key considerations in reimbursement decision-making for multiple sclerosis drugs in Australia. Multiple Sclerosis and Related Disorders, 2018, 25, 144-149.	0.9	3
58	My mind is made up: Cancer concern and women's preferences for contralateral prophylactic mastectomy. European Journal of Cancer Care, 2019, 28, e13058.	0.7	3
59	Preferences for HIV Testing Services and HIV Self-Testing Distribution Among Migrant Gay, Bisexual, and Other Men Who Have Sex With Men in Australia. Frontiers in Medicine, 2022, 9, 839479.	1.2	3
60	Rescuing Patients from the Rule of Efficiency. Pharmacoeconomics, 2003, 21, 681.	1.7	2
61	Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence. Pharmacoeconomics, 2017, 35, 347-362.	1.7	2
62	Understanding the financial impact of cancer: Examining the †COST' Measure in the Australian context Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e340.	0.2	2
63	LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open, 2021, 11, e054075.	0.8	2
64	Health Technology Assessment and Health Care Utilisation in the Management of Early Prostate Cancer. European Urology Focus, 2019, 5, 134-136.	1.6	1
65	What Does Metastasis-Free Survival Actually Mean?. Journal of Clinical Oncology, 2019, 37, 1679-1680.	0.8	1
66	Helping patients with lung cancer choose between surgery or stereotactic body radiotherapy: the importance of the patient experience. Journal of Thoracic Disease, 2019, 11, 4404-4407.	0.6	1
67	The "ProPSMA Study―clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy Journal of Clinical Oncology, 2019, 37, TPS138-TPS138.	0.8	1
68	Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base. European Urology Oncology, 2018, 1, 459-460.	2.6	0
69	P2.16-33 What Influences Patient Decision-Making About Lung-Cancer Treatment? A Discrete Choice Experiment. Journal of Thoracic Oncology, 2019, 14, S878.	0.5	0
70	Cost-effectiveness of a complex intervention in general practice to increase uptake of long-acting reversible contraceptives in Australiaâ€. Australian Health Review, 2021, 45, 728-734.	0.5	0
71	INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY. Neuro-Oncology, 2021, 23, vi106-vi107.	0.6	O
72	NIMG-49. A PROSPECTIVE, MULTI-CENTRE TRIAL OF FET-PET IN GLIOBLASTOMA PATIENTS - THE TROG 18.06 FIG STUDY: KEY ASPECTS OF IMAGING AND RADIATION ONCOLOGY CREDENTIALING. Neuro-Oncology, 2021, 23, vi140-vi140.	0.6	0

# ARTICLE IF CITATIONS

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel

<i>versus</i> standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical) Tj ETQq1 1 0.784314 rg T / Overl